Everyone is talking about…

Last month, the Joint Council for Cosmetic Practitioners (JCCP) released new guidance in relation to the remote prescribing of prescription-only medicines (POMs) for cosmetic treatments. This follows discussions about the upcoming licensing scheme for non-surgical cosmetic treatments after the Health and Care Bill (2022) was granted royal assent. In addition to this, the Botulinum Toxins and Cosmetic Fillers (Children) Act (2021) that came into force last year shows that momentous change within the sphere of medical aesthetics is no longer on the horizon, but it is now a reality.

The JCCP press release (2022) states:

‘… in line with the guidance set down by several Professional Statutory Regulators (the General Medical Council and the General Dental Council and in accordance with guidance set down by the Royal Pharmaceutical Society), the JCCP and the CPSA (Cosmetic Practice Standards Authority) have set down their decision not to endorse or permit the remote prescribing of any injectable prescription medicine and medical device when used for non-surgical cosmetic procedures’.